Artelo BiosciencesARTL -1.75%31 Current Ratio is 1.79 as of Mar. 2026, which is 62% below its 10-year median of 4.71. GuruFocus rates ARTL with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Artelo Biosciences ranks worse than 72.03% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Artelo Biosciences's current ratio for the quarter that ended in Mar. 2026 was 1.79.
Artelo Biosciences has a current ratio of 1.79. It generally indicates good short-term financial strength.
The historical rank and industry rank for Artelo Biosciences's Current Ratio or its related term are showing as below:
ARTL'
s Current Ratio Range Over the Past 10 Years
Min: 0.17 Med: 4.71 Max: 42.3
Current: 1.79
During the past 12 years, Artelo Biosciences's highest Current Ratio was 42.30. The lowest was 0.17. And the median was 4.71.
ARTL's Current Ratio is ranked worse than 72.03% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs ARTL: 1.79
Artelo Biosciences (NAS:ARTL) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Artelo Biosciences Current Ratio Related Terms
Artelo Biosciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Artelo Biosciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARTL vs RNAZ, GLMD, DCOY: Current Ratio Comparison
For the Biotechnology subindustry, Artelo Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artelo Biosciences (ARTL) has a Current Ratio of 1.79 as of Mar. 2026. This is 62% below median its historical median of 4.71. Over the past decade, Artelo Biosciences' Current Ratio has ranged from 0.17 to 42.30. According to the industry distribution chart, Artelo Biosciences ranks #1020 out of 1416 companies in the Biotechnology industry, placing it in the top 72%.
Is Artelo Biosciences' Current Ratio too high?
Artelo Biosciences' current Current Ratio of 1.79 is 62% below median its 10-year median of 4.71. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 42.30. The Biotechnology industry median Current Ratio is 3.89. Artelo Biosciences' value of 1.79 is 53.9% below this industry median. Based on the distribution chart, Artelo Biosciences ranks #1020 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Artelo Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Current Ratio compare to RNAZ and GLMD?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #1020 out of 1416 companies for Current Ratio. This places Artelo Biosciences in the lower half of its industry. The industry median Current Ratio is 3.89. Artelo Biosciences' value of 1.79 is 53.9% below this benchmark. Historically, Artelo Biosciences' own Current Ratio has ranged from 0.17 to 42.30 over the past decade. While the company's 10-year median is 4.71 vs. the industry median of 3.89, Artelo Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artelo Biosciences's current Current Ratio of 1.79 is 53.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artelo Biosciences's current Current Ratio is 1.79, which is 62% below median its own 10-year median of 4.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current Current Ratio of 1.79. The current Current Ratio is 1.79, which is 62% below median its 10-year median of 4.71 and 53.9% below the Biotechnology industry median of 3.89. Artelo Biosciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current Current Ratio is 1.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
31GF Score
Get the complete analysis for ARTL
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTL has been successfully added to your 
